Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Inclusion Criteria: * Eastern Cooperative Oncology Group performance status (ECOG PS) with no deterioration over the previous 2 weeks. * Progressive cancer at the time of enrollment. * Adequate organ and marrow function. Module 1: Part A: \- Participants must have one of the following: (i) Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C or RAD51D (ii) Histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D. (iii) Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC) and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes:BRCA1, BRCA2, PALB2, RAD51C, or RAD51D (d) Histologically or cytologically confirmed advanced/metastatic pancreatic cancer and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D. * Must have evaluable disease. * Must be suitable for treatment with a PARPi. * Must be capable of eating a high fat meal and adhering to fasting restrictions. Part B: * Must have metastatic or recurrent locally advanced histologically or cytologically confirmed Human Epidermal growth factor Receptor 2 (HER2)-negative carcinoma of the breast and evidence of a predicted loss of function germline or tumour mutation. * Must have at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter. * Participants who have received platinum chemotherapy for advanced breast cancer are eligible to enter the study provided there has been no evidence of disease progression during the platinum chemotherapy. * Participants who have received prior platinum-based chemotherapy as neo-adjuvant/adjuvant treatment are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and first dose of study intervention. Module 2: * Must be suitable for treatment with TMZ and have IDH1/2-mutant glioma. * Should have progressive disease after prior radiation therapy and one prior line of alkylating chemotherapy for their disease. * Recurrent disease must be evaluable by MRI. * Female participants of childbearing potential (CBP) must have a negative pregnancy test result at screening and prior to each cycle administration of AZD9574 and TMZ. * Adequate organ and marrow function. Module 3: Panel 1 * Must consent to provide mandated blood samples and archival/fresh tumour tissue for confirmatory tests of their cancer using central laboratory. * Participants must have one of the following: 1. Histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, 2. Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer and evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D 3. Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC) and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D. 4. Histologically or cytologically confirmed advanced/metastatic pancreatic cancer and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D. * Participants must have evaluable disease: at least one measurable and/or non-measurable lesions per RECIST 1.1 * Must be refractory to standard therapy or for which no standard therapy exists. * Any 2 participants in this panel must meet the following CNS criteria: 1. Must have previously treated and progressing or untreated brain metastases confirmed by brain MRI at screening that do not need immediate local therapy. 2. Should have stable neurological function for ≥ 14 days prior to signing the main study ICF. 3. If receiving steroids, the dose should be stable or decreasing for ≥ 14 days prior to signing the main study ICF. Panel 2 * Must be suitable for treatment with TMZ and have IDH1/2-mutant glioma. * Should have progressive disease after prior radiation therapy and one prior line of alkylating chemotherapy for their disease. * Recurrent disease must be evaluable by MRI and at least 1 tumour of \> 1cm diameter detected on MRI. * Formalin-fixed, paraffin-embedded (FFPE) tumour sample from the primary cancer must be available for central testing * Adequate organ and marrow function (in the absence of transfusions or growth factor support within 14 days prior to enrolment) Panel 3 * Must consent to provide mandated blood samples and archival/fresh tumour tissue for confirmatory tests of their cancer using central laboratory. * Must have histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D . * Must have evaluable disease: at least one measurable and/or non-measurable lesions per RECIST 1.1 . * Must be refractory to standard therapy or for which no standard therapy exists. Module 4: Part A: * Must have the following HER2 status: 1. Breast cancer must be IHC 3+ or IHC 2+/ISH-positive or IHC 2+/